ABSTRACT
Post-stroke dementia (PSD) includes all types of dementia after stroke, which may be the result of cumulative effects of cerebrovascular disease, Alzheimer's disease, and white matter changes. The incidence and prevalence of PSD are high. Its risk factors are mainly vascular risk factors, such as hypertension, atrial fibrillation, and diabetes. Other risk factors also include various imaging phenotypes of cerebrovascular disease, such as white matter hyperintensities, cerebral microbleeds, and brain atrophy. The clinical evaluation of PSD should be conducted at least 3-6 months after the onset of stroke. The prevention of PSD should focus on controlling vascular risk factors and preventing stroke.
ABSTRACT
Objective To screen out probable lynch syndrome (LS) associated endometrial cancer (EC) by investigating the expression of mismatch repair (MMR) protein in EC, and to analyze the disease traits combined with clinicopathologic characteristics. Methods The expressions of MSH2, MSH6, MLH1 and PMS2 were detected by using immunohistochemistry (IHC) in 443 EC patients. Results In 443 EC patients, 328 cases (74%) with all MMR proteins expression were classified as sporadic EC, and 115 cases (26%) cases with loss expression of at least one MMR protein were regarded as probable LS. MMR-deficient cases mostly showed a loss of MLH1/PMS2 expression (42%), followed by the absence of MSH2/MSH6 (23%), MSH6 (17%), PMS2 (17%) and MSH6/MLH1/PMS2 (3%). Compared with the sporadic EC group, obesity was not found in probable LS group (body mass index<28 kg/m2) (P=0.040), and high tumor grade was common (P=0.012); There was no significant difference between the two groups in age, the incidence of diabetes or hypertension, family history of cancer or histological type, tumor location, the International Federation of Gynecology and Obstetrics (FIGO) stage, myometrial invasion, lymph node metastasis, lymphatic or vascular invasion (all P> 0.05). A higher tumor grade was more common in the MSH6 and PMS2 deficient groups. Conclusions Compared with sporadic EC, the absence of obesity, a high grade tumor are more common in probable LS cases.
ABSTRACT
Objective To screen out probable lynch syndrome (LS) associated endometrial cancer (EC) by investigating the expression of mismatch repair (MMR) protein in EC, and to analyze the disease traits combined with clinicopathologic characteristics. Methods The expressions of MSH2, MSH6, MLH1 and PMS2 were detected by using immunohistochemistry (IHC) in 443 EC patients. Results In 443 EC patients, 328 cases (74%) with all MMR proteins expression were classified as sporadic EC, and 115 cases (26%) cases with loss expression of at least one MMR protein were regarded as probable LS. MMR-deficient cases mostly showed a loss of MLH1/PMS2 expression (42%), followed by the absence of MSH2/MSH6 (23%), MSH6 (17%), PMS2 (17%) and MSH6/MLH1/PMS2 (3%). Compared with the sporadic EC group, obesity was not found in probable LS group (body mass index<28 kg/m2) (P=0.040), and high tumor grade was common (P=0.012); There was no significant difference between the two groups in age, the incidence of diabetes or hypertension, family history of cancer or histological type, tumor location, the International Federation of Gynecology and Obstetrics (FIGO) stage, myometrial invasion, lymph node metastasis, lymphatic or vascular invasion (all P> 0.05). A higher tumor grade was more common in the MSH6 and PMS2 deficient groups. Conclusions Compared with sporadic EC, the absence of obesity, a high grade tumor are more common in probable LS cases.
ABSTRACT
Objective:To examine the expression of TRAF6 in esophageal organization from protein level and analyze the correlations between TRAF6 expression and clinical features.Methods: Seventy-eight patients with esophageal adenocarcinoma who were admitted to the Department of Oncology , Henan Province Hospital of TCM from January 2005 and January 2010 were finally eligible for present study and the corresponding esophageal normal tissues and clinical data were collected .All the specimens were confirmed by pathology for esophageal squamous cell carcinoma or esophageal normal tissues .The expression of TRAF6 in the tissue samples was detected by immunohistochemistry .The correlation between the TRAF6 expression and clinical characteristics of patients was analyzed.Results:The positive expression rate of TRAF 6 in esophageal cancer organizations and normal esophageal mucosal tissues were 71.79%and 10.26%,respectively.The positive expression rate of TRAF6 in esophageal cancer were significantly higher than those in normal esophageal mucosal tissue ( P0.05),but with lymph node metastasis and clinical stage (P<0.05).Patients with positive TRAF6 expression had significantly lower five-year survival rate than those with tumors having positive TAK1 expression.Conclusion:TRAF6 may play an important role in the pathology and development of squamous cell carcinoma ,and could be an important therapeutic target in the treatment of esophageal cancer .